B
ronchial asthma is a chronic inflammatory disease characterised by airway wall remodelling. Airway remodelling is due, at leas in part, to an excess of extracellular matrix deposition in the airway wall, which leads to subepithelial collagen deposition [1] . It has been speculated that this airway remodelling is an irreversible airway obstruction and is one of the factors that make asthma patients difficult to treat [1] . The histological characteristics of chronic inflammation include angiogenesis, increased connective tissue deposition and cellular proliferation of myofibroblasts. An increase in vessel size, vessel number and vascular surface area and the exaggerated expression of vascular endothelial growth factor (VEGF) are documented in the asthmatic airway [2] . It has been suggested that these vascular alterations contribute to the airway obstruction and/or airway hyperresponsiveness [3] .
VEGF is an endothelial cell-specific mitogenic peptide and plays a key role in vasculogenesis and angiogenesis. VEGF also increases vascular permeability so that plasma proteins, including inflammatory mediators and inflammatory cells, can leak into the extravascular space to allow the migration of inflammatory cells into the airways [4] . VEGF is a mediator of vascular and extravascular remodelling and inflammation, and thus the inhibition of VEGF may be a good therapeutic strategy [4, 5] . Although the mechanism by which VEGF could induce subepithelial fibrosis in asthmatic patients is not yet defined, it has been recently shown that VEGF exhibits a critical role in enhancing chronic T-helper type 2 cell (Th2)-mediated inflammation and transforming growth factor (TGF)-b 1 production [5] , which in turn may result in airway subepithelial fibrosis.
TGF-b 1 family proteins are influential regulators of tissue remodelling and act as potent inhibitors of proliferation for most cell types [6] , as well as show pro-inflammatory effects in various settings of inflammation. It has been well established that TGF-b 1 plays an important role in the pathogenesis of structural changes, including fibrosis, in a number of chronic lung diseases [7] . Furthermore, TGF-b 1 administration to mice has been shown to promote peribronchial collagen deposition [8] . However, the interactions between VEGF and TGF-b 1 in subepithelial fibrosis of allergic airway disease are poorly understood.
Phosphoinositide 3-kinase (PI3K) is a signal transduction enzyme that catalyses the phosphorylation of phosphatidylinositol (4,5)-bisphosphate to form phosphatidylinositol (3,4,5)-trisphosphate (PIP3) in response to activation of either receptor tyrosine kinase, G-protein coupled receptors or cytokine receptors, which ultimately regulate cell growth, differentiation, survival, proliferation, migration and cytokine production. Previous studies have suggested that PI3K contributes to the pathogenesis of asthma by effecting the recruitment, activation and apoptosis of inflammatory cells [9] [10] [11] . PI3K plays a key role in induction of the Th2 response [9] [10] [11] . This enzyme is also essential for interleukin (IL)-5-induced eosinophil release from bone marrow [10] and migration of eosinophils caused by a number of chemoattractants [11] . Enhanced basal activity of PI3K has been reported in eosinophils derived from allergic asthmatics [12] . Some studies have reported that PI3K inhibition reduces Th2 cytokine production, pulmonary eosinophilia, and airway inflammation and hyperresponsiveness in a mouse model of asthma [13, 14] . Additionally, PI3K signalling, including p110d isoform, is associated with the regulation of VEGF expression and activation [15, 16] . Along the same lines, PI3K has also been shown to play an important role in VEGFmediated signalling, and VEGF-induced PI3K activation has been linked to biologically diverse roles of VEGF, such as cell migration, vascular permeability, cell survival and cell proliferation [17] . Moreover, recent studies have revealed that PI3K plays a pivotal role in regulation of the TGF-b 1 expression [18, 19] .
In the present study, the potential role of VEGF on TGF-b 1 expression and the signal pathways involved in these processes in subepithelial fibrosis of allergic airway disease were investigated.
MATERIALS AND METHODS

Animals and experimental protocol
Female C57BL/6 mice, aged 8-10 weeks and free of murinespecific pathogens, were obtained from the Orientbio Inc. (Seoungnam, South Korea), housed throughout the experiments in a laminar flow cabinet and maintained on standard laboratory chow ad libitum. All experimental animals used in the present study were under a protocol approved by the Institutional Animal Care and Use Committee of the Chonbuk National University (Jeonju, South Korea). Standard guidelines for laboratory animal care were followed [20] . Mice were sensitised on days 1 and 14 by intraperitoneal injection of 20 mg ovalbumin (OVA; Sigma-Aldrich, St Louis, MO, USA) emulsified in 1 mg of aluminium hydroxide (Pierce Chemical Co., Rockford, IL, USA) in a total volume of 200 mL, as previously described, with some modifications [13, 21, 22] . On days 20, 21, 22, 23, 24 and 25 after the initial sensitisation, the mice were challenged for 30 min with an aerosol of 3% (weight/volume) OVA in saline (or with saline as a control) using an ultrasonic nebuliser (NE-U12; Omron, Tokyo, Japan). Bronchoalveolar lavage (BAL) was performed 72 h or 7 days after the last challenge. ), or vehicle control (0.05% dimethyl sulphoxide (DMSO)) diluted with 0.9% NaCl was administered intraperitoneally six times at 24-h intervals, beginning 1 h before the first challenge with OVA, as previously described, with some modifications [23] . Wortmannin (100 mg?kg ; BIOMOL Research Laboratories Inc., Plymouth Meeting, PA, USA), or vehicle control (0.05% DMSO) diluted with 0.9% NaCl was administered in a volume of 50 mL, as described previously, with some modifications [13] . Wortmannin or LY-294002 was administered intratracheally three times to each treated animal at 48-h intervals, beginning 1 h before the first challenge.
Administration
Western blot analysis
Protein expression levels were analysed by means of Western blot analysis, as described previously [13] . The blots were incubated with an anti-TGF-b 1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Akt antibody (Cell Signaling Technology Inc., Beverly, MA, USA), or antiphosphorylated Akt (anti-p-Akt) antibody (Cell Signaling Technology Inc.).
Measurement of TGF-b 1
Levels of TGF-b 1 were quantified in the supernatants of BAL fluids by enzyme immunoassays (R&D Systems Inc., Minneapolis, MN, USA).
Measurement of PI3K enzyme activity in lung tissues PI3K enzyme activity in lung tissues was measured as described previously [16] . The amount of PIP3 produced was quantified by PIP3 competition enzyme immunoassays (Echelon Inc., Salt Lake City, UT, USA).
Isolation and primary culture of murine tracheal epithelial cells Murine tracheal epithelial cells were isolated under sterile conditions, as previously described [13] . The trachea proximal to the bronchial bifurcation was excised and adherent adipose tissue was removed. The trachea was opened longitudinally and cut into three pieces. The isolated tracheas were incubated in Dulbecco's modified Eagle's medium (DMEM) containing 0.1% protease overnight at 4uC. Following tissue digestion, foetal bovine serum (FBS; 10% final concentration) was added to the medium to deactivate enzymes, undigested fragments of tissue were removed and tracheal epithelial cells were harvested by centrifugation at 1006g for 5 min. The epithelial cells were seeded onto 35-mm collagen-coated dishes for submerged culture. The growth medium DMEM/F-12 (SigmaAldrich) containing 10% FBS, penicillin, streptomycin and amphotericin B was supplemented with insulin, transferrin, hydrocortisone, phosphoethanolamine, cholera toxin, ethanolamine, bovine pituitary extract and bovine serum albumin. The cells were maintained in a humidified 5% CO 2 incubator at 37uC until they adhered.
Cell culture of A549 and measurement of TGF-b 1 A549 cells, a human lung epithelial cell line, were purchased from the American Type Culture Collection (Manassas, VA, USA). Cells were cultured in modified F-12K medium supplemented with 5% FBS, 100 U?mL -1 penicillin, and 100 mg?mL -1 streptomycin in a humidified 5% CO 2 incubator at 37uC. After reaching confluence, cells were harvested and then seeded onto 12-well plates for enzyme immunoassay. Cells were treated with various concentrations of recombinant human VEGF (R&D Systems Inc.) with or without wortmannin. Levels of TGF-b 1 were quantified in the supernatants of A549 cells by enzyme immunoassays according to the manufacturer's protocol (R&D Systems Inc.).
Histology and immunocytochemistry
For histological examination, 4-mm sections of fixed embedded tissues were cut on a Leica model 2165 rotary microtome (Leica, Nussloch, Germany), placed on glass slides, deparaffinised and stained sequentially with Masson's trichrome stain. For immunocytochemistry of TGF-b 1 , the cytocentrifuge preparations of BAL cells or of tracheal epithelial cells were incubated sequentially in accordance with the RTU Vectastain Universal Quick kit from Vector Laboratories Inc. (Burlingame, CA, USA). The slides were probed with an affinity-purified rabbit polyclonal TGF-b 1 immunoglobulin (Ig)G (Santa Cruz Biotechnology) overnight at 4uC and were incubated with prediluted biotinylated pan-specific IgG for 10 min.
Quantification of peribronchial fibrosis
Two methods (Masson's trichrome staining and total lung collagen content) were used to quantify peribronchial fibrosis.
Peribronchial trichrome staining
The area of peribronchial trichrome staining in a paraffinembedded lung was outlined and quantified using a light microscope (Leica DM LB; Leica Mikroskopie & Systeme GmbH, Wetzlar, Germany) attached to an image analysis system (analySIS Pro version 3.2; Soft Imaging System GmbH, Mü nster, Germany). Results were expressed as the area of trichrome staining per micrometer length of basement membrane of bronchioles 150-200 mm of internal diameter. At least 10 bronchioles were counted in each slide.
Determination of total lung collagen content
The total lung collagen content was determined using the Sircol Collagen Assay kit (Biocolor Ltd, Belfast, UK).
Determination of airway responsiveness to methacholine
Airway responsiveness was assessed as a change in airway function after challenge with aerosolised methacholine via the airways, as described elsewhere [16] . Anaesthesia was achieved with 80 mg?kg -1 of pentobarbital sodium injected intraperitoneally. The trachea was then exposed through midcervical incision, tracheostomised and an 18-gauge metal needle was inserted. Mice were connected to a computercontrolled small animal ventilator (flexiVent; SCIREQ, Montreal, QC, Canada). The mouse was quasi-sinusoidally ventilated with nominal tidal volume of 10 mg?kg -1 at a frequency of 150 breaths?min -1 and a positive end-expiratory pressure of 2 cmH 2 O (0.2 kPa) to achieve a mean lung volume close to that during spontaneous breathing. This was achieved by connecting the expiratory port of the ventilator to water column. Before methacholine challenge, an aerosol of saline was given to obtain baseline of airway responsiveness in each group. Methacholine aerosol was generated with an in-line nebuliser and administered directly through the ventilator. To determine the differences in airway response to methacholine, each mouse was challenged with methacholine aerosol in increasing concentrations (2.5-50 mg?mL -1 in saline). After each methacholine challenge, the data of respiratory system resistance (Rrs) were continuously collected. Maximum values of Rrs were selected to express changes in airway function, which was represented as a per cent change from baseline after saline aerosol.
Densitometric analyses and statistics
All immunoreactive and phosphorylative signals were analysed by densitometric scanning (Gel Doc XR; Bio-Rad Laboratories Inc., Hercules, CA, USA). Data are expressed as mean¡SEM. Statistical comparisons were performed using oneway ANOVA followed by the Scheffe's test. Significant differences between two groups were determined using unpaired t-test. Statistical significance was set at p,0.05.
RESULTS
Effects of VEGF inhibitors on TGF-b 1 levels in lung tissues
and BAL fluids of OVA-sensitised and -challenged mice Western blot analysis revealed that levels of TGF-b 1 protein in lung tissues were significantly increased at 7 days after the last inhalation of OVA, compared with the levels in the control mice (figs 1a and 1b). The increased TGF-b 1 levels after OVA inhalation were decreased significantly by the administration of SU5614 or CBO P-11. Consistent with these results, enzyme immunoassay revealed that the increased TGF-b 1 levels after the last OVA inhalation were decreased significantly by the administration of SU5614 or CBO-P11 ( fig. 1c) .
Effects of VEGF inhibitors on peribronchial fibrosis in lung tissues of OVA-sensitised and -challenged mice OVA-sensitised and -challenged mice (figs 2b, 2e and 2f) had a significant increase in levels of peribronchial and perivascular fibrosis compared with control mice (figs 2a, 2e and 2f), as assessed by trichrome staining and determination of total lung collagen content. The increased trichrome staining and collagen deposition after OVA inhalation was significantly decreased by the administration of SU5614 (figs 2c, 2e and 2f) or CBO-P11 (figs 2d, 2e and 2f) compared with that of untreated mice.
Effects of VEGF inhibitors on Akt phosphorylation and PI3K enzyme activity in lung tissues of OVA-sensitised and -challenged mice To support the contention that the increased VEGF protein in allergen-induced airway inflammation occurred through the PI3K pathway, Western blotting and PIP3 competition enzyme immunoassay were performed in order to determine Akt phosphorylation and to measure PI3K enzyme activity. Levels of p-Akt protein in the lung tissues were significantly increased 7 days after OVA inhalation, compared with the levels in the control mice (figs 3a and 3b) . However, no significant changes in Akt protein levels were observed in any of the groups tested. The increased p-Akt, but not Akt, protein levels in the lung tissues after OVA inhalation were significantly reduced by the administration of SU5614 or CBO-P11. The PI3K activity in the lung tissues was increased at 7 days after OVA inhalation, compared with that in the control mice ( fig. 3c) . The increased PI3K activity in the lung tissues after OVA inhalation was significantly decreased by the administration of SU5614 or CBO-P11.
Effects of PI3K inhibitors on TGF-b 1 levels in lung tissues
Western blot analysis revealed that levels of TGF-b 1 protein in lung tissues were significantly increased 7 days after the last inhalation of OVA, compared with the levels in the control mice ( fig. 4) . The increased TGF-b 1 levels after OVA inhalation were decreased significantly by the administration of LY-294002 or wortmannin.
Effects of PI3K inhibitors on total lung collagen deposition OVA-sensitised and -challenged mice had a significant increase in the levels of lung collagen deposition compared with control mice, as assessed by determination of total lung collagen content (fig. 5 ). The increased collagen deposition after OVA inhalation was significantly decreased by the administration of wortmannin or LY-294002, compared with that of untreated mice.
Effects of VEGF inhibitors on cellular changes in BAL fluids
Numbers of total cells, lymphocytes, neutrophils and eosinophils in BAL fluids were increased significantly 72 h after OVA inhalation, compared with the numbers after saline inhalation (data not shown). The increased numbers of total cells, lymphocytes, neutrophils and eosinophils were significantly reduced by the administration of SU5614 or CBO-P11.
Effects of VEGF inhibitors on airway hyperresponsiveness
Airway responsiveness was assessed as a per cent increase of Rrs in response to increasing doses of methacholine. In OVAsensitised and -challenged mice, the dose-response curve of per cent Rrs shifted to the left compared with that of control mice (data not shown). In addition, the per cent Rrs produced by methacholine administration (at doses 10-50 mg?mL -1 ) increased significantly in the OVA-sensitised and -challenged mice, compared with the controls. OVA-sensitised and -challenged mice treated with SU5614 or CBO-P11 showed a dose-response curve of per cent Rrs that shifted to the right compared with that of untreated mice. These results indicate that administration of SU5614 or CBO-P11 reduces OVAinduced airway hyperresponsiveness. 
DISCUSSION
Fibrosis is an important cause of morbidity and mortality in the lung. This is illustrated in airway disorders such as asthma, which is characterised by chronic inflammation and subepithelial/airway fibrosis [24] . TGF-b 1 is a multifunctional cytokine that plays pivotal roles in diverse biological processes, including tissue remodelling and repair [25] . In human chronic lung diseases like asthma, TGF-b 1 expression has been shown to be increased [26] . Moreover, TGF-b 1 administration promotes peribronchial collagen deposition [8] and the increase of TGF-b 1 expression in asthma patients seems to correlate with disease severity and the degree of subepithelial fibrosis [27] . Although some Th2-inflammatory mediators, such as IL-13 and IL-11, are known to have the ability to enhance TGF-b 1 expression, the exact mechanisms for the regulation of TGF-b 1 expression remain to be elucidated. A recent study has demonstrated that VEGF enhances TGF-b 1 production [5, 18] , which, in turn, may result in airway subepithelial fibrosis. However, the mechanism by which VEGF induces subepithelial fibrosis, specifically the relationship between VEGF and TGF-b 1 in allergic airway disease, is not yet defined. The present study involving the OVA-induced model revealed the following typical pathophysiological features of allergic airway disease in the lungs: increased numbers of airway inflammatory cells, bronchial hyperresponsiveness, increased peribronchial fibrosis and increased levels of VEGF and TGF-b 1 . Administration of VEGF inhibitors reduced these pathophysiological signs of allergic airway disease and decreased the increase of TGF-b 1 levels and peribronchial fibrosis after OVA inhalation. These findings suggest that inhibition of VEGF attenuates peribronchial fibrosis by preventing TGF-b 1 production in allergic airway disease.
VEGF is a potent stimulator of inflammation, airway remodelling and physiological dysregulation that augments antigen sensitisation and Th2 inflammation [5] . VEGF can be produced by a wide variety of cells, including macrophages, neutrophils, eosinophils and lymphocytes [4] . Several studies have also shown that overproduction of VEGF causes airway inflammation and bronchial hyperresponsiveness [4] . Consistent with these observations, the present results have revealed that airway inflammatory cells and bronchial hyperresponsiveness after OVA inhalation were substantially increased and that the administration of VEGF inhibitors reduced the increase of airway inflammation and bronchial hyperresponsiveness. Recently, VEGF has been found to be a mediator of airway fibrosis that is a feature of airway remodelling [28, 29] . VEGF can increase the expression of connective tissue growth factor, a growth factor that acts on fibroblast proliferation and matrix production [28] , and stimulate fibronectin secretion from human airway muscle cells [29] . In addition to these in vitro studies, LEE et al. [5] , using VEGF transgenic mice, have clearly demonstrated that VEGF is a potent inducer both of angiogenesis and subepithelial fibrosis. CHETTA et al. [30] have also reported that VEGF expression is associated with subepithelial fibrosis in humans. Consistent with these observations, the present study found that VEGF expression was upregulated and peribronchial fibrosis was also increased in OVA-induced allergic airway disease. Intriguingly, administration of the VEGF inhibitors SU5614 or CBO P-11 significantly reduced the increase of peribronchial fibrosis induced by OVA inhalation. Taken together, these findings suggest that VEGF may contribute to airway wall remodelling in allergic airway disease by affecting the extracellular matrix composition and by stimulating fibrotic changes.
Since PI3K was first identified as an activity associated with various oncoproteins and growth factor receptor [31] , accumulating evidence has indicated that PI3Ks can provide a critical signal for cell proliferation, cell survival, membrane trafficking, glucose transport, neurite outgrowth, membrane ruffling and superoxide production, as well as actin reorganisation and chemotaxis [32] . PI3K activity is also stimulated after antigen challenge in a murine model of allergic asthma, and administration of wortmannin or LY-294002, two broadspectrum inhibitors of PI3Ks, attenuates inflammation and airway hyperresponsiveness [13, 14] . Moreover, several studies have demonstrated that PI3K is involved in mediating the various biological functions of VEGF [17, 33] . Consistent with these observations, the present results have shown that p-Akt protein and PI3K enzyme activity were significantly increased after OVA inhalation and the increased levels of activity were substantially reduced by treatment with VEGF inhibitors SU5614 or CBO-P11.
A recent study has revealed that VEGF induces TGF-b 1 mRNA expression and protein production [18] . In keeping with these results, the current authors have found that inhibition of VEGF decreased the increased expression of TGF-b 1 in the lungs after OVA inhalation. Using highly specific PI3K inhibitors, wortmannin or LY-294002, it was possible to elucidate whether VEGF regulates the TGF-b 1 expression through the PI3K signalling pathway in a murine model of allergic airway disease. It has been shown that administration of PI3K inhibitors significantly reduced the increase of TGF-b 1 levels in lungs after OVA inhalation. These findings are consistent with previous evidence that activation of the PI3K/Akt pathway is important for TGF-b 1 expression [18, 19] . In addition, the present authors have found that TGF-b 1 production in human lung epithelial cells were induced by VEGF and that treatment of lung epithelial cells with wortmannin significantly reduced the production of TGF-b 1 induced by VEGF. Taken together, these observations suggest that inhibition of VEGF attenuates increased peribronchial fibrosis, at least through reduction of TGF-b 1 expression mediated by the PI3K/Akt pathway in allergic airway disease.
Hypoxia-inducible factor (HIF)-1 is a transcriptional factor that functions as a master regulator of oxygen homeostasis. HIF-1 has been shown to regulate the expression of dozens of target genes, including VEGF, the protein products of which play important roles in angiogenesis, erythropoiesis, energy metabolism and cell survival [34] . HIF-1 is a heterodimer composed of an oxygen-regulated HIF-1a subunit and a constitutively expressed HIF-1b subunit [35] . In addition to the oxygendependent regulation of HIF-1a expression and activity, an oxygen-independent regulatory pathway has been identified through which a variety of cytokines and growth factors have been shown to induce the expression of HIF-1a and HIF-1 target genes [36] . These cytokines and growth factors induce HIF-1a expression via the activation of phosphorylated signalling pathways, including the PI3K/Akt pathway [37] . In addition, several studies have demonstrated that activation of the PI3K/Akt pathway causes the increase of HIF-1a protein levels [38] . Consistent with these observations, determination of HIF-1a protein levels in nuclear extracts has revealed that this protein level was substantially increased in the present mouse model of allergic airway disease and that the increased HIF-1a activity was significantly reduced by the administration of wortmannin or LY-294002 (data not shown). Therefore, these findings imply that the HIF-1a activation after OVA inhalation may depend on PI3K signalling, which is induced by VEGF in allergic airway disease. Moreover, the current authors have found that the administration of VEGF inhibitors reduced the OVA-induced increased VEGF expression itself, as well as PI3K activity, and have previously reported that the increased HIF-1a activity via PI3K/Akt signalling activation increased the expression of VEGF in a murine model of allergic airway disease [15, 16] . Taken together, the present authors suggest that a positive feedback loop between HIF-1a and VEGF exists in allergic airway disease.
In summary, the present data strongly indicate that the inhibition of vascular endothelial growth factor signalling is potentially powerful therapeutic strategy for subepithelial fibrosis of allergic airway disease, partly mediated by regulation of transforming growth factor-b 1 expression through the phosphoinositide 3-kinase/Akt pathway. Therefore, these findings provide an important mechanism for the use of vascular endothelial growth factor inhibitors to prevent and/ or treat subepithelial fibrosis in allergic airway disease. 
